Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expression/DNA Methylation of Cancer Testis Antigens May Predict Response to Pembrolizumab in Non-small Cell Lung Cancer Patients

NCT03571360 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT03571360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03571360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expression/DNA Methylation of Cancer Testis Antigens May Predict Response to Pembrolizumab in Non-small Cell Lung Cancer Patients
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Unknown status
Start date
February 10, 2020
Completion date
July 14, 2021
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer